← Back to patent-cliff list
RTP-026
Tier C — Watch / tradeRTP-026
ResoTher Pharma APS
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FPR2
Indications (approved)：ST段抬高型心肌梗死, Myocardial infarction
Regional status
US
-
EU
Phase II
2024-07-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RTP-026?
Approved indications include: ST段抬高型心肌梗死, Myocardial infarction.
When does the RTP-026 patent expire?
No public expiry year is available for RTP-026 yet; this page updates once verified.
How do I get a quote for RTP-026 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01